Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - risperidone 37,5 mg - powder and solvent for prolonged-release suspension for injection - 37,5 mg - risperidone 37.5 mg - risperidone

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

janssen-cilag sa-nv - risperidone 37,5 mg - powder and solvent for suspension for injection - 37,5 mg - risperidone 37.5 mg - risperidone

New Zealand - English - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - risperidone 37.5mg - suspension for injection - 37.5 mg/2ml - active: risperidone 37.5mg excipient: polyglactin carmellose sodium citric acid dibasic sodium phosphate dihydrate polysorbate 20 sodium chloride sodium hydroxide water for injection - risperdal consta is indicated for the treatment of schizophrenia and other psychotic disorders. these include first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted effect, emotional and social withdrawal, poverty of speech) are prominent. risperdal consta also alleviates affective symptoms (such as depression, guilt-feelings, anxiety) associated with schizophrenia. in addition, risperdal consta also appears effective in maintaining the clinical improvement during continuation therapy in patients who have should an initial response to treatment with this agent.

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - risperidone -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - risperidone -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - risperidone -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - risperidone -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - risperidone -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risperidone, quantity: 4 mg - tablet, film coated - excipient ingredients: lactose monohydrate; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; hypromellose; indigo carmine aluminium lake; maize starch; propylene glycol; purified talc; quinoline yellow aluminium lake; sodium lauryl sulfate; titanium dioxide - treatment of schizophrenia and related psychoses.,short term treatment of acute mania associated with bipolar 1 disorder (see dosage and administration: bipolar mania).,treatment of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe demetia of the alzheimer type). *(see dosage and administration: behavioural disturbances in dementia),risperidone is indicated for the treatment *(up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. *(see dosage and administration: behavioural disturbances in dementia),treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data).,treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - risperidone, quantity: 3 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; hypromellose; maize starch; propylene glycol; purified talc; quinoline yellow aluminium lake; sodium lauryl sulfate; titanium dioxide - treatment of schizophrenia and related psychoses.,short term treatment of acute mania associated with bipolar 1 disorder (see dosage and administration: bipolar mania).,treatment of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe demetia of the alzheimer type). *(see dosage and administration: behavioural disturbances in dementia),risperidone is indicated for the treatment *(up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type. *(see dosage and administration: behavioural disturbances in dementia),treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data).,treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).